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Abstract
Background: Accurate identification of underlying health conditions is important to fully adjust for confounders in
studies using insurer claims data. Our objective was to evaluate the ability of four modifications to a standard
claims-based measure to estimate the prevalence of select comorbid conditions compared with national
prevalence estimates.
Methods: In a cohort of 11,973 privately insured women aged 18–64 years with mastectomy from 1/04–12/11 in
the HealthCore Integrated Research Database, we identified diabetes, hypertension, deficiency anemia, smoking,
and obesity from inpatient and outpatient claims for the year prior to surgery using four different algorithms. The
standard comorbidity measure was compared to revised algorithms which included outpatient medications for
diabetes, hypertension and smoking; an expanded timeframe encompassing the mastectomy admission; and an
adjusted time interval and number of required outpatient claims. A χ2 test of proportions was used to compare
prevalence estimates for 5 conditions in the mastectomy population to national health survey datasets (Behavioral
Risk Factor Surveillance System and the National Health and Nutrition Examination Survey). Medical record review
was conducted for a sample of women to validate the identification of smoking and obesity.
Results: Compared to the standard claims algorithm, use of the modified algorithms increased prevalence from 4.
79 to 6.79 % for diabetes, 14.75 to 24.87 % for hypertension, 4.23 to 6.65 % for deficiency anemia, 1.78 to 12.87 %
for smoking, and 1.14 to 6.31 % for obesity. The revised estimates were more similar, but not statistically equivalent,
to nationally reported prevalence estimates. Medical record review revealed low sensitivity (17.86 %) to capture
obesity in the claims, moderate negative predictive value (NPV, 71.78 %) and high specificity (99.15 %) and positive
predictive value (PPV, 90.91 %); the claims algorithm for current smoking had relatively low sensitivity (62.50 %) and
PPV (50.00 %), but high specificity (92.19 %) and NPV (95.16 %).
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Conclusions: Modifications to a standard comorbidity measure resulted in prevalence estimates that were closer to
expected estimates for non-elderly women than the standard measure. Adjustment of the standard claims
algorithm to identify underlying comorbid conditions should be considered depending on the specific conditions
and the patient population studied.
Keywords: Comorbidity, Administrative health claims data, Diabetes, Hypertension, Obesity, Mastectomy, Breast
cancer
Background
Adjusting for comorbidities in observational studies is
essential to account for underlying differences in popula-
tions under investigation. This is especially true when
studying healthcare utilization, costs, and patient out-
comes, in which underlying comorbid conditions are as-
sociated with the outcomes. The Charlson index [1], a
widely-used measure of 19 comorbidities, was adapted
for administrative data using ICD-9-CM (International
Classification of Diseases, 9th Revision, Clinical Modifi-
cation) codes [2, 3]. A second commonly used comor-
bidity measure with claims data developed by Elixhauser
includes 29 medical conditions [4, 5]. These measures
were developed and validated in hospitalized patients,
and therefore may be more applicable to older, sicker
populations.
A number of studies have compared the performance of
the Charlson and Elixhauser measures [6–12]. The best
measure has generally been determined based on im-
provement in explanatory power with regard to a specific
outcome, usually mortality. Many studies have concluded
that that these measures perform equally well [7, 9–11],
while others have found the Elixhauser classification
improved prediction of in-hospital [8, 12] and longer-
term mortality [6, 12]. Several investigators have ex-
panded the parameters of these two comorbidity mea-
sures to include physician [10, 13–15], outpatient,
and auxiliary claims [10, 14, 15] and different look-
back periods relative to the index event (e.g., one or
two years of prior data and/or including the index
admission) [10, 12, 14, 15].
We have an ongoing study of risk factors for postoper-
ative complications in women under the age of 65 years
after mastectomy and breast reconstruction using com-
mercial insurer claims data [16, 17]. Breast reconstruc-
tion is most commonly performed in younger women
[18] who have fewer underlying medical conditions (M.
Olsen, unpublished results, National Inpatient Data) and
lower annual healthcare costs than elderly women [19],
suggesting less healthcare utilization. Fewer healthcare
encounters and hospitalizations could limit the identifi-
cation of comorbid conditions in claims data. For ex-
ample, methods that perform well in elderly populations,
e.g., using only diagnoses on inpatient hospital claims,
may not be optimal for younger, generally healthy popu-
lations with infrequent hospitalizations.
To address some of the challenges of capturing comor-
bidities in younger populations, we selected diabetes,
hypertension, anemia (including iron, folate, vitamin B12,
protein, and other nutritional deficiency anemias), smok-
ing, and obesity as representative examples of commonly
occurring underlying health conditions in younger per-
sons, and to illustrate the impact of modifications to the
standard claims algorithm to improve capture of comor-
bidities. One alteration included the addition of diagnosis
codes during the index hospital admission, to capture con-
ditions that might be more commonly coded during a
hospitalization than during prior outpatient encounters.
All five conditions we included in our study pertain to this
example, since they may be considered relevant to care
provided during an inpatient hospitalization, but may not
be relevant to service(s) or procedure(s) rendered during
an outpatient visit, a requirement for health insurance
coding [20]. Another alteration included allowing only a
single diagnosis code to identify conditions for which test-
ing is not necessary, such as obesity and smoking. A third
alteration consisted of relaxing the requirement for spa-
cing of diagnoses coded during outpatient encounters at
least 30 days apart, because of the potential for clustering
of care within a short time frame in younger women diag-
nosed with breast cancer. We also examined the effect of
prescription drug claims to identify a condition, using
hypertension and diabetes as relevant conditions. Our ob-
jective was to compare the impact of these modifications
to the standard claims algorithm to identify a comorbid
health condition, using the expected population preva-
lence of the comorbid health condition and medical rec-
ord review to signal improvement.
Methods
Data source
We conducted a retrospective cohort study using the
HealthCore Integrated Research Database (HIRDSM).
We used data in the HIRDSM from individuals enrolled
in 12 Anthem-affiliated plans for this study. Anthem is
an independent licensee of the Blue Cross and Blue
Shield Association and serves its members as the Blue
Cross licensee (California), and the Blue Cross and Blue
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Shield licensee (Colorado, Connecticut, Georgia, Indiana,
Kentucky, Maine, Missouri (excluding 30 counties in the
Kansas City area), Nevada, New Hampshire, New York,
Ohio, Virginia (excluding the Northern Virginia suburbs
of Washington, DC), and Wisconsin). Data in the HIRDSM
include all fully-adjudicated claims submitted for reim-
bursement from providers, facilities, and outpatient phar-
macies linked to health plan enrollment information.
Fully insured women with health plan enrollment that
included non-capitated medical coverage of hospital and
physician services and prescription drug coverage were
eligible for inclusion in the study cohort. Men were ex-
cluded due to the rare incidence of breast cancer in men.
Women lacking continuous coverage from 365 days be-
fore through 30 days after mastectomy were excluded
since comorbid conditions could not be fully measured.
Additional exclusions included women with diagnosis
codes for end-stage renal disease because of potentially in-
complete claims, ICD-9-CM diagnosis code or prescrip-
tion claim suggesting HIV positive status at any time for
privacy considerations, and organ transplant in the year
before mastectomy due to the rare nature of their under-
lying illness. Claims were restricted to paid claims.
The study data contained up to 5 ICD-9-CM diag-
nosis codes and 5 ICD-9-CM procedure codes per
claim among women with a mastectomy in 2004–
2008 and up to 12 ICD-9-CM diagnosis codes and 8
ICD-9-CM procedure codes among women with a
mastectomy in 2009–2011. Inpatient facility claims
also included Uniform Billing (UB-04) revenue and
Healthcare Common Procedure Coding System
(HCPCS) codes, while outpatient facility and provider
claims included Current Procedural Terminology, 4th
edition (CPT-4) and HCPCS codes. Pharmacy claims
contained National Drug Codes, which were linked to
Generic Product Identifier codes to identify medica-
tions and drug groups.
Patient population
We identified mastectomy operations among women aged
18–64 years from 1/1/2004–12/31/2011 using ICD-9-CM
procedure codes 85.41–85.48 from inpatient facility claims
and/or CPT-4 procedure codes 19180, 19200–19240,
19303, and 19305–19307 from outpatient facility and pro-
vider claims. We included only the first mastectomy per
woman during the time period. The patient population
was further refined by excluding operations coded by a
provider- or facility-only without additional evidence for
operation (i.e., anesthesia, pathology, or surgery revenue
code) and mastectomy with codes for breast-conserving
surgery if provider and other claims suggested breast-
conserving surgery was more likely to increase the chance
that a mastectomy was performed [17].
Comorbidity algorithms
We used the ICD-9-CM diagnosis codes from the
Elixhauser classification [4] to define diabetes, hyperten-
sion, anemia, and obesity (see Additional file 1). Since
smoking is not included in the Elixhauser list of comor-
bidities; we used ICD-9-CM diagnosis codes for history
of tobacco use and tobacco disorder to define smoking.
We did not restrict the identification of conditions by
diagnosis-related group [4] since we wanted to identify
all relevant comorbid conditions at the time of mastec-
tomy. We examined the impact of outpatient prescrip-
tion claims for medications used to treat diabetes,
hypertension, and smoking cessation to enhance the de-
tection of these conditions (see Additional file 1). In
order to focus on diagnoses recorded by clinicians, we
excluded provider and outpatient facility claims contain-
ing only CPT-4 or UB-04 revenue codes for pharmacy,
diagnostic radiology/cardiology/pulmonology, clinical la-
boratory, physical/occupational therapy, speech path-
ology or ambulance services. The timeframe used to
identify comorbid conditions, frequency and interval be-
tween outpatient and provider claims, and use of pre-
scription drug claims were changed sequentially to
determine how the changes impacted the final preva-
lence calculated for each underlying condition (Table 1).
For the standard claims algorithm (Algorithm 1), we
used medical claims from −365 through −1 days before
mastectomy and required ≥ 2 provider or outpatient fa-
cility claims spaced > 30 days apart or ≥ 1 inpatient claim
to identify comorbid conditions, as described by Klabunde
[13]. For algorithm 2, we expanded the timeframe to cap-
ture comorbid conditions in medical claims through 7 days
after mastectomy. While the standard claims algorithm
described by Klabunde does not include identification of
comorbid conditions during the hospital admission be-
cause some conditions could have new onset during the
hospital admission (e.g., blood loss anemia, electrolyte dis-
turbances), the comorbid conditions we selected for these
analyses were most likely pre-existing at the time of mast-
ectomy. Additionally, our study population consisted of
younger, privately insured women with a low frequency of
inpatient hospitalizations in the year prior to mastectomy,
giving little opportunity to identify comorbid conditions
in prior inpatient admissions. We suspected that some
health conditions would be more likely to be coded during
the mastectomy hospitalization (e.g., smoking) because of
its relevance to surgery, so this provided additional motiv-
ation to determine the impact of adding the surgical
hospitalization to the algorithm to identify underlying
health conditions.
The frequency and interval requirements for provider/
outpatient facility claims were altered in algorithm 3. Be-
cause of potential clustering of medical encounters in
women with a diagnosis of breast cancer, we considered ≥
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2 provider/outpatient facility claims consistent with the
diagnosis of interest (i.e., dropped the requirement for
spacing of outpatient diagnoses > 30 days apart). For
smoking and obesity, we considered single provider/out-
patient facility claim(s) sufficient evidence since these con-
ditions do not require diagnostic workup.
One or more prescription claims for medications to
treat diabetes (oral hypoglycemic, insulin), hypertension,
and smoking cessation from −365 to −1 days before
mastectomy were added to algorithm 4 to detect these
conditions (see Additional file 1). At least one medical
claim with a hypertension diagnosis was required in
addition to a prescription claim for an anti-hypertensive
medication, since drugs used for hypertension may also
be used to treat other conditions.
Comparison populations
Survey results from the 2007 Behavioral Risk Factor Sur-
veillance System (BRFSS) [21] and 2000 National Health
and Nutrition Examination Survey (NHANES) [22] were
used for the national estimates of the prevalence for
each of the comorbid conditions. To best approximate
our privately insured mastectomy cohort, weighted esti-
mates for diabetes, hypertension, smoking, and obesity
were calculated from female BRFSS respondents aged
18–64 years old with health insurance. In the surveys
diabetes and hypertension were captured by the question
“Have you ever been told by a doctor that you have (dia-
betes/high blood pressure)?” In both surveys BMI was
defined using reported height and weight, and current
smoking was defined on the basis of two questions:
“Have you smoked at least 100 cigarettes in your entire
life?” and “Do you now smoke cigarettes every day, some
days, or not at all?” The prevalence of iron deficiency
anemia (used as a proxy for all nutritional deficiency
anemia) among adult females was available in a publica-
tion referencing NHANES data [22]. In the NHANES
survey iron deficiency anemia was defined based on la-
boratory results from the respondent’s blood sample.
The age group level prevalence estimates from the
NHANES publication were averaged for 20–64 year olds
to establish a single prevalence estimate for deficiency
anemia. Because obesity is a risk factor for breast cancer
[23], and hypertension and diabetes are more prevalent
in obese persons, we assumed that women undergoing
mastectomy would have higher rates of the selected con-
ditions than the survey populations. While the survey
populations may not be a gold-standard, the prevalence
rates should serve as a baseline threshold for compari-
son to our study population.
For additional comparisons, a subset of the privately
insured mastectomy population with postoperative ICD-
9-CM diagnosis code(s) suggestive of wound complica-
tions was selected for medical record review. We se-
lected this subset in order to validate the ICD-9-CM
diagnosis codes for wound complications (manuscript in
preparation), in addition to validation of the codes for
obesity and smoking. For this subset height, weight, and
current and past smoking history were abstracted from
the medical records. Body mass index (BMI) ≥ 30 was
used to define obesity.
Analysis
Wald confidence intervals were calculated for each con-
dition prevalence estimate. A chi-square test of propor-
tions was used to compare the different algorithms in
Table 1 Parameters for each algorithm used to identify comorbidities






Interval and number of
provider or outpatient




Algorithm 1 Diabetes, hypertension,
deficiency anemia, smoking,
obesity
−365 to −1 1+ 2+ more than 30 days apart n/a
Algorithm 2 Diabetes, hypertension,
deficiency anemia, smoking,
obesity
−365 to +7 1+ 2+ more than 30 days apart n/a
Algorithm 3 Diabetes, hypertension,
deficiency anemia
−365 to +7 1+ 2+ n/a
Smoking, obesity −365 to +7 1+ 1+ n/a
Algorithm 4 Diabetes −365 to +7
−365 to −1 Rx
1+ 2+ 1+
Hypertension −365 to +7
−365 to −1 Rx
1+ 2+ 1+ Rx plus 1
hypertension medical
claim
Smoking −365 to +7
−365 to −1 Rx
1+ 1+ 1+
n/a not applicable
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the mastectomy cohort and estimates from BRFSS and
NHANES. Sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) were
calculated to compare smoking and obesity data from
the claims to the medical record results. All data man-
agement and statistical analyses were performed using
SAS v9.3 (SAS Institute Inc., Cary, NC). This study was
approved by the Human Research Protection Office at
Washington University and by the Quorum Review IRB
for the research activity at HealthCore.
Results
The mastectomy cohort included 11,973 women aged 18–
64 years with at least one year of health insurance enroll-
ment prior to mastectomy from 1/1/2004–12/31/2011.
The average age of women in the population was 51 years,
and all 4 regions of the U.S. were represented in the co-
hort (Table 2). More than 60 % of women underwent
mastectomy for locally invasive breast cancer, and 59 % of
women had immediate reconstruction at the time of mast-
ectomy, primarily involving an implant.
For all five conditions, each successive change to the
comorbidity algorithm resulted in an increase in
prevalence of the condition (Fig. 1). Compared to the
standard claims algorithm (algorithm 1), the revised
prevalence estimates increased from 4.79 % (95 % confi-
dence interval [CI] 4.40, 5.17) to 6.79 % (95 % CI 6.34,
7.24) for diabetes, 14.75 % (95 % CI 14.11, 15.39) to
24.87 % (95 % CI 24.10, 25.65) for hypertension, 4.23 %
(95 % CI 3.87, 4.60) to 6.65 % (95 % CI 6.20, 7.09) for
anemia, 1.78 % (95 % CI 1.54, 2.02) to 12.87 % (95 % CI
12.27, 13.47) for smoking, and 1.14 % (95 % CI 0.95,
1.33) to 6.31 % (95 % CI 5.88, 6.75) for obesity.
Impact of successive changes to comorbidity algorithm
The impact of each successive change to the algorithm
varied by comorbid condition (Fig. 1). When the time-
frame was expanded to include diagnoses coded during
the surgical admission (algorithm 2), the percentage of
women with diabetes, hypertension, anemia, smoking,
and obesity increased 19, 37, 26, 319, and 196 %, re-
spectively. The impact of dropping the requirement for
spacing of provider/outpatient claims > 30 days apart in
algorithm 3 resulted in an additional 5 % increase in dia-
betes, 8 % for hypertension, and 25 % for anemia. Re-
quiring only a single provider/outpatient claim for
smoking and obesity in algorithm 3 resulted in increased
prevalence of smoking (70 %) and obesity (88 %) com-
pared to algorithm 2. Finally, the addition of prescription
claims in algorithm 4 increased the percentage of
women with diabetes by 13 %, hypertension by 14 %,
and smoking by 2 % (Fig. 1). Each successive change
from one algorithm to the next resulted in a statistically
significant increase in the comorbid condition preva-
lence with two exceptions (algorithm 4 and smoking, al-
gorithm 3 and diabetes).
We conducted a sensitivity analysis to see if the per-
formance of the algorithms to identify comorbid health
conditions varied by age (Table 3). We found the great-
est overall percent improvement compared to algorithm
1 in the youngest age group (18–47 years) for diabetes,
hypertension, and obesity, while improvement was great-
est for deficiency anemia and smoking in the middle age
group (48–55 years).
In the final algorithm for each comorbid condition (i.e.,
algorithm 3 for anemia and obesity, algorithm 4 for dia-
betes, hypertension, and smoking), provider/outpatient fa-
cility claims contributed more to the prevalence
estimate than inpatient facility claims (Table 4). Pre-
scription drug claims captured more women with dia-
betes than either inpatient facility or outpatient
facility/provider claims alone. For hypertension, pre-
scription claims plus at least a single coded medical
claim identified more women than were identified by
either a single inpatient facility or ≥ 2 outpatient facil-
ity/provider claims. In contrast, smoking cessation
Table 2 Characteristics of 11,973 women in the mastectomy
population
Characteristic n (%)
















flap plus implant reconstruction
418 (3.49)
Bilateral mastectomy 4,995 (41.72)
Indication for mastectomy
Metastatic cancer 298 (2.49)
Regional cancer 2,385 (19.92)
Local breast cancer 7,381 (61.65)
Carcinoma in situ 1,529 (12.77)
Prophylactic 308 (2.57)
Benign/other 72 (0.60)
Inpatient operation 9,733 (81.29)
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Fig. 1 Comparison of Prevalence Estimates for Comorbidities by Algorithm Compared to National Estimates. * Significantly different from
national estimate
Table 3 Comparison of prevalence estimates for comorbidities by age tertile and improvement by algorithm












to algorithm 1, %
Diabetes 1 1.39 4.56 8.57
2 1.92 38.13 5.26 15.35 10.11 17.97
3 2.09 50.36 5.62 23.25 10.46 22.05
4 2.64 89.93 6.35 39.25 11.57 35.01
Hypertension 1 5.62 14.14 24.93
2 8.45 50.36 19.16 35.50 33.38 33.89
3 9.24 64.41 20.98 48.37 35.59 42.76
4 11.04 96.44 24.00 69.73 40.23 61.37
Deficiency
anemia
1 4.44 4.35 3.67
2 5.47 23.20 5.86 34.71 4.66 19.18
3 6.77 52.48 7.37 69.43 5.82 48.85
Smoking 1 1.78 1.61 1.94
2 7.03 294.94 7.94 393.17 7.41 281.96
3 11.96 571.91 13.51 739.13 12.55 546.91
4 12.20 585.39 13.77 755.28 12.70 554.64
Obesity 1 0.84 1.28 1.31
2 2.79 232.14 3.49 172.66 3.86 194.66
3 5.07 503.57 6.20 384.38 7.74 490.84
a See Table 1 for description of each algorithm
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prescription claims did not add significantly to the
prevalence estimate of smoking (Table 4).
We examined the combination of data sources coded
for individual conditions and relevant medications
(Fig. 2). In algorithm 4, 32 % of women who met the
definition for diabetes and 34 % of women with hyper-
tension had both provider/outpatient facility claims and
medication claims for the condition. Thirty percent of
women with diabetes and 29 % with hypertension were
coded positive in all three data sources (i.e., inpatient fa-
cility, provider/outpatient facility, and prescription drug).
Provider/outpatient facility claims alone were the most
common source coded for anemia (73 %), smoking
(49 %), and obesity (58 %), followed by coding on in-
patient facility claims alone with 19, 32, and 29 % re-
spectively. Only a small percentage had both inpatient
facility and provider/outpatient facility claims positive
for anemia, smoking, or obesity (8, 16, and 13 %,
respectively).
To determine the clustering of coding of diagnoses be-
fore mastectomy in this younger population, we analyzed
the diagnosis codes present on medical claims in the
month prior to mastectomy. In this time period, 64 % of
the diagnoses on medical claims related to the diagnosis
of breast cancer (invasive or in situ cancer, history of
breast cancer) or suspicion of cancer (e.g., mammo-
graphic abnormality, lump in breast). Invasive or in situ
cancer codes were particularly common, accounting for
44 % of all diagnoses on medical claims in the month
prior to mastectomy.
Prevalence of comorbid conditions in claims data versus
national estimates
We calculated national estimates for the prevalence of
diabetes (6.01 %), hypertension (19.84 %), smoking
(17.63 %) and obesity (25.51 %) in adult insured women
under the age of 65 years using data from the 2007
BRFSS, and used the estimate of iron deficiency anemia
(3.67 %) derived from the 2000 NHANES [22]. The re-
vised estimate of diabetes prevalence in our mastectomy
population calculated by algorithms 2 (5.70 %; p = 0.160)
and 3 (6.00 %; p = 0.952) and the estimate of hyperten-
sion prevalence calculated in algorithm 2 (20.15 %; p =
0.402) were not significantly different from the national
estimates (Fig. 1).
Comorbid condition prevalence in claims data by year
and compared to medical record review
We compared the prevalence of the five comorbid con-
ditions among women with mastectomy in 2004–2008
versus 2009–2011 to look at the impact of the increase
in ICD-9-CM diagnosis code fields in the HIRDSM from
5 to 12 (see Additional file 1). For diabetes, hyperten-
sion, smoking, and obesity, the prevalence was signifi-
cantly higher in 2009–2011 for all 4 algorithms
compared to the earlier time period. The prevalence of
anemia was higher among women with mastectomy in
2004–2008, although it did not reach statistical signifi-
cance for algorithm 2.
We abstracted information on current smoking and
height and weight to calculate BMI from the medical re-
cords of 290 women in the cohort, although not all re-
cords contained the specific documentation (75 % had
information on smoking and 60 % of records had both
weight and height). The specificity of coding for both
current and ever-smoking and for obesity was very high
(Table 5). The PPV of coding was high for both condi-
tions, although the PPV for coding was lower when
smoking was defined as current smoking. Conversely,
the sensitivity and NPV of coding for smoking were
higher when coded smoking was compared to current
smoking status documented in the medical record, ra-
ther than ever smoked. For obesity, the specificity and
PPV were high and the sensitivity and NPV were low for
all 3 algorithms (Table 5). The BMI for obese women
who were coded with ICD-9-CM diagnosis codes for
obesity in claims was significantly higher than the BMI
in obese women with no encounters coded for obesity
(median BMI 40.20 vs. 32.85, p < 0.001, Mann–Whitney
U test).











Inpatient facility 366 (3.06) 1,382 (11.54) 215 (1.80) 746 (6.23) 314 (2.62)
Provider or outpatient facility 637 (5.32) 2,147 (17.93) 642 (5.36) 1,017 (8.49) 540 (4.51)
Prescription drug 641 (5.35) 2,577 (21.52) b n/a 61 (0.51) n/a
Inpatient facility, provider, or outpatient
facility (algorithm 3)
718 (6.00) 2,603 (21.74) 796 (6.65) 1,515 (12.65) 756 (6.31)
Inpatient facility, provider, outpatient facility,
or prescription drug (algorithm 4)
813 (6.79) 2,978 (24.87) b n/a 1,541 (12.87) n/a
n/a not applicable
a Final algorithm was algorithm 3 for deficiency anemia and obesity and algorithm 4 for diabetes, hypertension, and smoking; see Table 1 for description of
each algorithm
b By definition all with Rx had at least one facility or provider medical claim
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Discussion
We found progressively increasing prevalence of comor-
bid conditions in a population of younger women who
underwent mastectomy by including the surgical admis-
sion to identify conditions, eliminating minimum spa-
cing or need for more than one outpatient/provider
claims coded for the condition, and identifying
conditions with prescription claims, where possible. For
all comorbid conditions, each change to the algorithm
resulted in additional women detected with the under-
lying health condition and prevalence values closer to
the national estimates for insured adult women, particu-
larly for the younger women in our population. These
five comorbid conditions served as illustrative examples
Fig. 2 Claim Sources Used to Define Comorbidities in Final Algorithm* Among Those Positive for the Comorbidity. INP = inpatient facility claim,
OP/MD = outpatient facility or provider claim, Rx = prescription drug claim. *algorithm 3 for deficiency anemia and obesity, algorithm 4 for
diabetes, hypertension, and smoking
Table 5 Results of chart validation of smoking and obesity compared with insurance claims
Chart and claims, n Chart only, n Claims only, n Not in chart or claims, n Sensitivity, % Specificity, % PPV, % NPV, %
Smoking per claims algorithma versus current smoker in chartb
Algorithm 1 4 20 1 191 16.67 99.48 80.00 90.52
Algorithm 2 12 12 7 185 50.00 96.35 63.16 93.91
Algorithm 3 15 9 14 178 62.50 92.71 51.72 95.19
Algorithm 4 15 9 15 177 62.50 92.19 50.00 95.16
Smoking per claims algorithma versus current or former smoker in chartb
Algorithm 1 5 62 0 150 7.46 100.00 100.00 70.75
Algorithm 2 18 49 1 149 26.87 99.33 94.74 75.25
Algorithm 3 24 43 5 145 35.82 96.67 82.76 77.13
Algorithm 4 25 42 5 145 37.31 96.67 83.33 77.54
Obesity per claims algorithma versus BMI≥ 30 in chartb
Algorithm 1 4 52 0 118 7.14 100.00 100.00 69.41
Algorithm 2 7 49 0 118 12.50 100.00 100.00 70.66
Algorithm 3 10 46 1 117 17.86 99.15 90.91 71.78
BMI body mass index, PPV positive predictive value, NPV negative predictive value
a See Table 1 for description of each algorithm
b Among those with non-missing information in the medical chart (n = 216 current smoker, n = 217 current or former smoker, n = 174 BMI)
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of the range of opportunities to increase capture of co-
morbid conditions depending on the specific characteris-
tics of the condition.
The inclusion of diagnosis codes from the mastectomy
admission resulted in substantially increased prevalence
of smoking, obesity, and hypertension. This finding is in
agreement with previous studies which found the
addition of diagnosis codes from the index admission
was important to more accurately capture underlying
comorbidities [10, 12, 15]. One explanation for this in-
crease in prevalence could be the relevance of these con-
ditions at the time of surgery. In the month prior to
mastectomy in this younger population, 64 % of the
diagnoses coded on medical claims concerned the acute
diagnosis (e.g., breast cancer, mammographic abnormal-
ity). Diagnoses of comorbid conditions may not have
been considered relevant until the inpatient surgical ad-
mission, when hypertension, obesity, and smoking are
important considerations in the administration of
anesthesia and operative care. The inclusion of diagnoses
from the mastectomy admission is justified for the co-
morbid conditions we chose to analyze since they are
unlikely to arise during the mastectomy hospitalization.
There was a small but significant increase in the
prevalence of hypertension and anemia when any two
coded provider/outpatient facility claims were consid-
ered evidence for the condition, dropping the require-
ment for coding during encounters spaced at least
30 days apart. This may also be due to the younger
mastectomy population we studied, in which healthcare
encounters for workup and treatment are clustered dur-
ing a relatively short time interval. We are unaware of
any other studies that have assessed the spacing of out-
patient claims. There was a large increase in prevalence
of smoking and obesity when only one provider/out-
patient facility claim was required to establish the diag-
nosis. The requirement of ≥ 2 outpatient/provider claims
to identify a condition was incorporated in comorbidity
algorithms to account for inaccuracy in coding on out-
patient claims [13, 24], and the lack of specific codes for
diagnostic workup. Since no testing is required to estab-
lish the diagnosis of obesity or smoking, we removed the
requirement for coding during multiple encounters,
resulting in an 88 and 70 % increase in the prevalence of
obesity and smoking, respectively. The resulting increase
put the calculated 12.65 % smoking prevalence in our
privately insured population much closer to the 2007 na-
tional estimate of current smoking in non-elderly adult
women of 17.63 %.
Finally, the addition of outpatient prescription claims
significantly increased the calculated prevalence of dia-
betes and hypertension, and in fact prescription claims
identified more women with diabetes than medical
claims. Medications have been used to identify chronic
conditions alone [25–28], or in combination with
diagnosis codes on medical claims [29, 30]. Adding
medications to a medical claims algorithm improved
identification of osteoporosis in a Canadian study [31, 32].
In contrast, prescription claims for smoking deterrents
were uncommon and did not add to the prevalence esti-
mate for smoking. Other investigators have used out-
patient pharmacy data to estimate the prevalence of
several chronic conditions, and found good agreement
with health survey data for chronic conditions treated
with specific agents, including diabetes and thyroid
disorders [33]. The estimated prevalence of chronic
conditions based on prescription drug utilization was
higher than national estimates based on survey data
in some studies [33, 34].
We found that the calculated prevalence for diabetes
and hypertension in the mastectomy population were
higher than prevalence estimates for women aged 18–64
years using the BRFSS and NHANES data. This could be
due to the association of diabetes and hypertension with
increased incidence of breast cancer [35–37]. Our calcu-
lated prevalence of anemia, which included iron defi-
ciency and other anemias, may be higher than the
national estimate since the NHANES testing was limited
to iron deficiency anemia. In addition, the prevalence of
anemia may be higher in the mastectomy population
since some women may have developed anemia second-
ary to neoadjuvant chemotherapy, which could have
been coded using a diagnosis code in our algorithm for
“deficiency” anemia.
In contrast, our calculated prevalence of obesity was
much lower than the estimated national prevalence of
26 % in non-elderly adult women, likely due to the low
sensitivity (18 %) of ICD-9-CM diagnosis codes to iden-
tify obesity that we found in medical record review. The
very low sensitivity and high PPV of ICD-9-CM diagno-
sis codes to identify obesity in our study has also been
reported for ICD-10 codes in Canada [38]. In our med-
ical record validation we found that the median BMI for
obese women with an ICD-9-CM diagnosis code for
obesity was higher than the BMI of obese women who
were not coded for obesity in the prior year, suggesting
that morbid obesity is more likely to be coded than
obesity per se. Supporting this is the similarity of the
6.31 % prevalence of coded obesity in our mastectomy
population to the 8.29 % prevalence of morbid obesity in
the NPCR Breast Cancer study [39].
Similarly, the prevalence of smoking in the mastec-
tomy population defined by one or more encounters
coded for tobacco use disorder was 12.87 %, lower than
the 2007 national estimate of 17.63 % from the BRFSS.
Our lower prevalence may be due to the relatively low
sensitivity (62.50 %) of coding for smoking we found
compared to current smoking documented in the
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medical records. Coding of tobacco history or disorder
had higher sensitivity to identify current smokers than
ever smokers (62.50 % vs. 37.31 %, respectively), but the
PPV was lower for current compared to ever-smoking.
These results suggest that tobacco use coding has rela-
tively high specificity, but may not distinguish between
current and former smokers.
For all comorbid conditions other than anemia, the
prevalence estimates were higher when 12 diagnosis
code fields were available in the later time period of the
database rather than 5 fields. The trends of increasing
prevalence with sequential changes in our coding algo-
rithm were the same in both time periods. The reason
for the lower prevalence of anemia in the later years of
the study (2009–2011) may be due to the addition of a
specific diagnosis code for antineoplastic chemotherapy-
induced anemia in 2009, which is not included in the
standard comorbidity category of anemia.
We found greatest improvement in our final algorithm
in the younger third of the population compared with
the older women in the cohort for diabetes, hyperten-
sion, and obesity. We hypothesized that comorbidities
may not be captured as well among younger women
with existing algorithms, owing to their different pat-
terns of healthcare utilization compared to older women,
which proved true for these three comorbid conditions.
While improvements in capture of the five conditions
we studied were evident in the older age groups as well
(albeit to a lesser extent), particularly for anemia and
smoking, these women in our cohort may be more simi-
lar to the older, sicker populations that were used to de-
velop the traditional comorbidity algorithms [1, 4, 13].
Previous studies have compared claims-based comor-
bidity measures or modifications based on improvement
in ability to predict an outcome, rather than improved
accuracy of condition identification. Most investigators
have based improvement in comorbidity measures on
improvement in model performance (e.g., concordance
statistic) to predict mortality [7–10, 12, 14, 29, 40–43],
although other outcomes such as healthcare costs [44,
45], readmissions [30], and progression of disease [41]
have also been assessed. In contrast, we compared the
prevalence of comorbidities calculated using claims data
to health condition estimates in adult women of the
same age reported in the BRFSS and NHANES survey
populations. While we compared survey respondents with
similar demographics to our population with respect to
age, sex, and insurance status (BRFSS only), these national
estimates may still not be completely comparable to the
breast cancer population. The prevalence of a given co-
morbid condition in our commercially insured population
may vary by other demographics that we could not ac-
count for, such as state of residence and type of insurance.
In addition, the national estimates from the BRFSS survey
are subject to limitations including self-report and recall
bias.
We utilized a population of younger women undergoing
mastectomy in order to assess modifications of a comorbid-
ity algorithm in a non-elderly population. The patterns of
healthcare utilization in our population of women, the
majority of whom were newly diagnosed with breast cancer,
may be different from other populations; therefore the
generalizability of our findings is unknown. Future studies
to determine if our findings hold in other non-elderly surgi-
cal and non-surgical populations, in men, and in patients
with other types of health insurance are warranted. Men in
particular have different patterns of healthcare utilization
that may impact the performance of the algorithm.
Conclusions
We found progressively increasing prevalence of diabetes,
hypertension, and anemia using claims data from a large
population of non-elderly adult women undergoing mast-
ectomy by altering the standard claims-based comorbidity
algorithm to include diagnosis codes assigned during the
surgical admission and removal of the requirement for
spacing of diagnosis codes in outpatient encounters.
Addition of outpatient pharmacy claims resulted in fur-
ther increases in the calculated prevalence of diabetes and
hypertension. We found progressively increasing preva-
lence of obesity and smoking by including diagnosis codes
assigned during the surgical admission and by requiring
only one coded inpatient or outpatient encounter, al-
though medical record review to verify coding accuracy
revealed low sensitivity of ICD-9-CM diagnosis codes to
identify both health conditions. An important strength of
our study is the large, longitudinal, population-based sam-
ple of younger persons representing hundreds of facilities
from different geographic regions and different practice
patterns. We assessed improvement in the coding algo-
rithms compared to national survey estimates of the
prevalence of the conditions in adult, non-elderly, insured
women. Our results suggest a “one size fits all” approach
to identifying comorbid conditions in claims data may not
be the best way to identify individuals with a particular
condition, and that investigators performing studies using
claims data in younger, privately insured individuals may
want to modify their strategy based on the particular co-
morbid conditions of interest. Additional research investi-
gating strategies to optimize identification of comorbid
health conditions in younger populations is needed to
confirm these findings.
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